PR NEWSWIRE:

Australis Capital Invests $3 Million in CBD Extraction Company

By: Australia Capital Inc 
January 13, 2018

Australis Capital Invests in Folium Biosciences a Global Leader in Non-Psychoactive Cannabinoid Production

LAS VEGAS, Jan. 14, 2019 /PRNewswire/ – Australis Capital Inc. (CSE: AUSA) (“Australis” or the “Company”) is pleased to announce the Company has invested $3,000,000 USD in Folium Biosciences (“Folium”), the largest vertically integrated producer, manufacturer, and distributor of hemp derived phytocannabinoids in the United States. Folium also owns and operates the largest phytocannabinoid extraction and purification facility in the United States, with plans for a new pharmaceutical division and the completion of their Canadian facility in 2019.

“With the passing of the 2018 Farm Bill and the floodgates opening for this vibrant and exciting industry, we are poised for strong growth this year,” said Kashif Shan, CEO of Folium. “As a global industry leader and authority in PCR hemp oil extraction and product development, we welcome Australis’ participation in this private placement as we continue to pave the way and dominate the marketplace.”

Supplying the market with its own unique 0.0% THC phytocannabinoid-rich hemp oil, Folium is a global leader in non-psychoactive cannabinoids. Folium’s chromatographic purification process selectively removes the psychoactive component from the phytocannabinoid-rich hemp oil. Folium is certified by the Colorado Department of Public Health and Environment as a producer of 0.0% THC products, including CBD hemp oil, CBD gel caps, water-soluble CBD, Cannabidiol HYDROPCR, CBD e-liquid, CBD concentrates, CBD for pets, CBD salves and balms, CBD tinctures, CBD face masks, and white-label CBD products.
Our strategic investment in Folium Biosciences provides Australis and our brand’s access to the leading player in the fast-evolving United States CBD market. Folium’s breadth of expertise, spanning production, extraction, branding, and commercialization, will greatly benefit Australis as we introduce and expand our CBD product offerings in the United States in the months and years ahead.

About Australis Capital Inc.
Australis Capital identifies and invests in the cannabis industry predominately in the United States, a highly regulated, fragmented, rapidly expanding and evolving industry. Investments may include and are not limited to equity, debt or other securities of both public and private companies, financings in exchange for royalties or other distribution streams, and control stake acquisitions.  Australis Capital adheres to stringent investment criteria and will focus on significant near and mid-term high-quality opportunities with strong return potentials while maintaining a steadfast commitment to governance and community. Australis Capital’s Board members and Management have material experience with, and knowledge of, the cannabis space in the U.S., extensive backgrounds in highly regulated industries, adherence to stringent regulatory compliance, public company and operational expertise. In addition to the Company’s expertise and strong execution on strategic M&A, which to date includes Rthm Technologies Inc., Body and Mind Inc. and Quality Green Inc., Australis has developed strategic partnerships with companies such as Wagner Dimas.

Australis’ Common shares trade on the CSE under the symbol “AUSA”.

For further information about Australis, please visit the website at ausacap.com or contact the Company by e-mail at [email protected]